{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    41,
    42,
    43,
    44,
    45,
    46,
    47,
    48,
    49
  ],
  "modelUsed": "gemini-3-flash-preview",
  "interventions": {
    "studyInterventions": [
      {
        "id": "int_1",
        "name": "Canagliflozin",
        "type": {
          "id": "e3f7008b-a875-4e8e-a400-44597fb245c0",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "role": {
          "id": "338552f6-b56a-46f6-b14b-0d35d8e260c5",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus and diabetic nephropathy.",
        "productIds": [
          "prod_1"
        ],
        "administrationIds": [
          "admin_1"
        ]
      },
      {
        "id": "int_2",
        "name": "Placebo",
        "type": {
          "id": "070af6e9-a207-43be-a27e-c409ffc20edc",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "role": {
          "id": "9e6fa8e5-b4f5-4611-b8bb-a0610250d8e2",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Matching placebo capsules for single-blind run-in and double-blind treatment phases.",
        "productIds": [
          "prod_2"
        ],
        "administrationIds": [
          "admin_2"
        ]
      },
      {
        "id": "int_3",
        "name": "ACEi or ARB",
        "type": {
          "id": "ed5c3f58-36a9-441a-9c77-2d813dc43c64",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "role": {
          "id": "04670ab0-cd25-4169-a7a3-33171ab891df",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Maximum tolerated labeled daily dose of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker required for at least 4 weeks prior to randomization."
      },
      {
        "id": "int_4",
        "name": "Antihyperglycemic agents (AHA)",
        "type": {
          "id": "f2a7dc2f-1e68-42db-9eba-02d2826ff596",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "7a3762e4-d1d8-4dbb-9de1-dfaad57a26ae",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Background AHA regimen adjusted to achieve glycemic goals using standard local guidelines."
      },
      {
        "id": "int_5",
        "name": "Mineralocorticoid receptor antagonist (MRA)",
        "type": {
          "id": "317a2a25-c062-4a07-b87d-2f6508114c19",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "312ac2bc-afb1-4605-8285-eba168f3ac96",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Restricted post-baseline use permitted if medically necessary; requires frequent monitoring of serum potassium."
      },
      {
        "id": "int_6",
        "name": "Direct renin inhibitor (DRI)",
        "type": {
          "id": "795d4c44-5313-43e8-aced-0357332b8d5e",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "9fd8d37e-2486-4b20-9b99-7ecaa9a00756",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Subjects must be off therapy for at least 8 weeks prior to randomization."
      },
      {
        "id": "int_7",
        "name": "SGLT2 inhibitors",
        "type": {
          "id": "0adec449-7db6-43b7-b6a6-190bdf98f9ff",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "4aaaffd6-704c-4390-a500-3da8e48be94b",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Current use of other SGLT2 inhibitors is prohibited."
      }
    ],
    "administrableProducts": [
      {
        "id": "prod_1",
        "name": "Canagliflozin capsules",
        "administrableDoseForm": {
          "id": "e58b8159-45d5-44b2-8aa4-dcf3666f8626",
          "code": "C25158",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Capsule",
          "standardCode": {
            "id": "aeb530fe-7fb8-4503-9690-f0d2b14ddc4e",
            "code": "C25158",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Capsule",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "d23ef404-8918-4266-9235-e0c2ba947249",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "100 mg",
        "substanceIds": [
          "sub_1"
        ],
        "manufacturer": "Janssen Research & Development"
      },
      {
        "id": "prod_2",
        "name": "Placebo capsules",
        "administrableDoseForm": {
          "id": "297ac499-124e-436c-b6a9-1ae27ecf346c",
          "code": "C25158",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Capsule",
          "standardCode": {
            "id": "f6c9fc19-01e4-4c6c-8f15-9e636a0a074b",
            "code": "C25158",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Capsule",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "570772f6-51f3-4299-91ae-b3a6173ecd33",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "0 mg",
        "manufacturer": "Janssen Research & Development"
      }
    ],
    "administrations": [
      {
        "id": "admin_1",
        "name": "Single-blind Run-in",
        "instanceType": "Administration",
        "dose": "1 capsule",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "2 weeks"
      },
      {
        "id": "admin_2",
        "name": "Double-blind Treatment",
        "instanceType": "Administration",
        "dose": "100 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Estimated 5 to 5.5 years (event-driven)"
      }
    ],
    "substances": [
      {
        "id": "sub_1",
        "name": "Canagliflozin",
        "instanceType": "Substance",
        "description": "JNJ-28431754; (1S)-1,5-anhydro-1-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol"
      }
    ],
    "medicalDevices": [],
    "summary": {
      "interventionCount": 7,
      "productCount": 2,
      "deviceCount": 0
    }
  },
  "rawResponse": {
    "interventions": [
      {
        "name": "Canagliflozin",
        "role": "Investigational Product",
        "description": "Sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus and diabetic nephropathy."
      },
      {
        "name": "Placebo",
        "role": "Placebo",
        "description": "Matching placebo capsules for single-blind run-in and double-blind treatment phases."
      },
      {
        "name": "ACEi or ARB",
        "role": "Background Therapy",
        "description": "Maximum tolerated labeled daily dose of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker required for at least 4 weeks prior to randomization."
      },
      {
        "name": "Antihyperglycemic agents (AHA)",
        "role": "Concomitant Medication",
        "description": "Background AHA regimen adjusted to achieve glycemic goals using standard local guidelines."
      },
      {
        "name": "Mineralocorticoid receptor antagonist (MRA)",
        "role": "Concomitant Medication",
        "description": "Restricted post-baseline use permitted if medically necessary; requires frequent monitoring of serum potassium."
      },
      {
        "name": "Direct renin inhibitor (DRI)",
        "role": "Concomitant Medication",
        "description": "Subjects must be off therapy for at least 8 weeks prior to randomization."
      },
      {
        "name": "SGLT2 inhibitors",
        "role": "Concomitant Medication",
        "description": "Current use of other SGLT2 inhibitors is prohibited."
      }
    ],
    "products": [
      {
        "name": "Canagliflozin capsules",
        "doseForm": "Capsule",
        "strength": "100 mg",
        "manufacturer": "Janssen Research & Development"
      },
      {
        "name": "Placebo capsules",
        "doseForm": "Capsule",
        "strength": "0 mg",
        "manufacturer": "Janssen Research & Development"
      }
    ],
    "substances": [
      {
        "name": "Canagliflozin",
        "description": "JNJ-28431754; (1S)-1,5-anhydro-1-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol"
      }
    ],
    "administrations": [
      {
        "name": "Single-blind Run-in",
        "dose": "1 capsule",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "2 weeks"
      },
      {
        "name": "Double-blind Treatment",
        "dose": "100 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "Estimated 5 to 5.5 years (event-driven)"
      }
    ],
    "devices": []
  }
}